As we celebrate International Clinical Trials Day #ICTD2021, Alzheimer’s Research UK (ARUK) has published a new report, calling for urgent improvements to how research is promoted and how clinical trails for dementia are delivered in the UK.
Clinical trials offer early access to potential treatments for people enrolled in them, as well as benefitting UK life sciences.
The ARUK report highlights the challenges dementia clinical trials currently face in the UK. These include:
- Only a small number of people eligible to take part in dementia clinical trials actually do so – just 2% of those diagnosed with dementia are part of Join Dementia Research (JDR), the leading registry for dementia research in the UK.
- Lack of awareness among people diagnosed with dementia about opportunities to take part in clinical research.
- Poor links between clinical research and dementia services, resulting in lack of awareness of opportunities to take part in research initiatives.
- Slow study approval process, leading to delays, and pharma companies choosing to delivery trials in other countries.
- Few people diagnosed at the very early stages, which is when many new trials are targeting trials
The ARUK report makes a number of recommendations which will need to be acted upon by research funders, regulators, health providers, NHS, Government and clinicians if the overall aims are to be achieved.Read the full report on the ARUK website